兄弟科技(002562.SZ)全資子公司取得原料藥CEP證書
格隆匯5月19日丨兄弟科技(002562.SZ)公佈,公司全資子公司江西兄弟醫藥有限公司於近日收到歐洲藥品質量管理局簽發的原料藥歐洲藥典適用性證書(以下簡稱“CEP證書”)。
原料藥名稱:IOPAMIDOL/碘帕醇。碘帕醇在臨牀上主要用於腰、胸及頸段脊髓造影,腦血管造影,周圍動、靜脈造影,心血管造影,冠狀動脈造影,尿路、關節造影及CT增強掃描。其具有對血管及神經的毒性低、局部及全身的耐受性好、滲透壓低等特點。目前,碘帕醇原料藥全球市場需求量預計超2,000噸,全球擁有大規模碘帕醇原料藥供應能力的廠商主要有Bracco、司太立等。
本次兄弟醫藥取得碘帕醇原料藥CEP證書,標誌着公司該原料藥可以在承認CEP證書的國際市場進行銷售,為公司碘帕醇原料藥進一步拓展國際市場帶來積極的影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.